Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a clinical-stage biotech company with a focus on developing precision medicine anti-cancer therapeutics for patients with high unmet medical needs. Its lead program, Stenoparib, is a promising drug that is being developed with a drug-specific companion diagnostic, leveraging its proprietary Drug Response Predictor (DRP) technology. Despite minimal current revenue, the company has a positive outlook due to its potential for significant growth and valuation in the future, while acknowledging the high risks involved in drug development. However, risks to its share price target include factors such as balance sheet and liquidity risks, failure to obtain regulatory approvals, and changes in macroeconomic factors and investor sentiment.

Bears say

Allarity Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Drug Response Predictor (DRP) platform to improve patient selection for its lead program Stenoparib, currently in Phase 2 trials for ovarian and small cell lung cancer. While the company's focus on precision medicine is promising, there are concerns about the drug's long development timeline and commercialization risks, as well as the company's minimal revenue generation and debt levels. Despite potential for growth in the large PARP inhibitor market and positive clinical data, the analyst maintains a negative outlook due to these risks, adjusting estimates for EPS and maintaining a sell rating with a 12-month price target of $9.75 based on a NPV analysis.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.